Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | DGKA | P23743 | 2/20 | 0.60 |
| ▸ | PAM | P19021 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | PRKCA | P17252 | 3/20 | 0.47 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.46 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.46 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3503234 | 1.00 | TSHR (0.66) | TSHRDGKAPAMMAPTLMNA | |
| SCHEMBL3505613 | 1.00 | TSHR (0.66) | TSHRDGKAPAMMAPTLMNA | |
| SCHEMBL2418388 | 0.98 | TSHR (0.62) | TSHRDGKAPAMMAPTLMNA | |
| SCHEMBL581108 | 0.87 | ALDH1A1 (0.61) | TSHRDGKAALDH1A1 | |
| SCHEMBL4055143 | 0.87 | ALDH1A1 (0.61) | TSHRDGKAALDH1A1 | |
| SCHEMBL581109 | 0.87 | ALDH1A1 (0.61) | TSHRDGKAALDH1A1 | |
| SCHEMBL1054427 | 0.87 | ALDH1A1 (0.61) | TSHRDGKAALDH1A1 | |
| SCHEMBL3503715 | 0.87 | ALDH1A1 (0.61) | TSHRDGKAALDH1A1 | |
| SCHEMBL7707401 | 0.87 | ALDH1A1 (0.61) | TSHRDGKAALDH1A1 | |
| SCHEMBL756947 | 0.87 | ALDH1A1 (0.61) | TSHRDGKAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112624920-A | Synthesis method of 4-palmitoyloxy-2-methyl-2-butenal and synthesis method of vitamin A palmitate | 北京藏卫信康医药研发有限公司 | 2021-04-09 | — | — | CN | claimed |
| CN-112624920-B | Synthesis method of 4-palmitoyloxy-2-methyl-2-butenal and synthesis method of vitamin A palmitate | 北京藏卫信康医药研发有限公司 | 2023-08-29 | — | — | CN | disclosed |
| CN-111484407-B | Preparation method of 1-halogenated-2-methyl-4-substituted carbonyloxy-2-butene | 新发药业有限公司 | 2023-04-07 | — | — | CN | disclosed |
| CN-112624920-A | Synthesis method of 4-palmitoyloxy-2-methyl-2-butenal and synthesis method of vitamin A palmitate | 北京藏卫信康医药研发有限公司 | 2021-04-09 | — | — | CN | disclosed |
| US-7767852-B2 | Removal by salt formation | BASF AKTIENGESELLSCHAFT (DE) | 2010-08-03 | — | — | US | disclosed |
| US-20080083606-A1 | preparing aminodihalophosphines, diaminohalophosphines, triaminophosphines, phosphorous ester diamides, aminophosphines, diaminophosphines, phosphorous ester amide halides and aminophosphine halides with elimination of an acid in the presence of an auxiliary base | BASF AKTIENGESELLSCHAFT (DE) | 2008-04-10 | — | — | US | disclosed |
| US-7351339-B2 | Using an auxiliary base to form a salt with the acid which is liquid at low enough temperature so that value product does not decompose during the removal of the liquid salt; e.g. acid catalyst removal; ionic liquids | BASF AKTIENGESELLSCHAFT (DE) | 2008-04-01 | — | — | US | disclosed |
| US-20050020857-A1 | Removal by salt formation | BASF AKTIENGESELLSCHAFT (DE) | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020857-A1 | Removal by salt formation | PHOSPHO1, AASDHPPT, INPP5B | TSHR 1936/4885DGKA 320/4885PAM 932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.